Filters
An artificially intelligent olfactory system has the potential to detect Parkinson’s disease through the odour profile of sebum, as shown in a study.
Percutaneous transforaminal endoscopic discectomy (PTED) is as effective as open microdiscectomy in alleviating leg pain caused by lumbar disc herniation, results of a trial have shown. PTED can thus be considered as an alternative to open microdiscectomy in the treatment of sciatica.
New drug applications approved by US FDA as of 16-28 February 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The use of wearable devices is feasible for the automated seizure detection in the home environment, leading to better care outcomes, such as fewer seizure-related injuries and more accurate seizure diaries, according to a recent study.
Eptinezumab reduces migraine days for both episodic and chronic migraine patients, and the drug’s efficacy and safety profile are independent of age, sex, and body mass index, as shown in a study.
Quantitative sensory testing (QST) yields reliable measures of pain threshold and tolerance, reveals a new study. However, measurements for sensitivity to changes in temperature are less reliable and may be affected by time and other contextual factors.
Patients with chronic obstructive pulmonary disease (COPD) and allied conditions are at heightened risk of stroke, but treatment with mucolytic agents and the combination of inhaled corticosteroids (ICS) plus long-acting β2-agonists (LABA) may protect against the risk, as shown in a study.
Common genetic variants associated with general cognition contribute to better verbal memory and semantic fluency in adults, according to a study. However, they appear to have a null effect on age-related cognitive decline.
Women who experienced a stroke during pregnancy had higher rates of morbidity and mortality compared with those without stroke, according to a study presented at ISC 2022.
The risk of recurrent venous thrombosis in patients with cerebral venous thrombosis (CVT) was comparable between those who received warfarin or direct oral anticoagulants (DOACs), according to results of the ACTION-CVT* study presented at ISC 2022.
